Clinical Cancer Research, Vol 3, Issue 6 1017-1022, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells

A Ogata, D Chauhan, M Urashima, G Teoh, SP Treon and KC Anderson
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA.

Interleukin 6 (IL-6) is a growth factor for multiple myeloma (MM) cells, yet not all MM cell lines or patient cells require IL-6 for their growth. It is well known that IL-6 activates the signal transducers and activators of transcription (stat) 1-stat3 heterodimer, stat3 homodimer, and Ras-dependent mitogen-activated protein kinase (MAPK) cascades in multiple cell systems. We have shown previously that the MAPK pathway is an important pathway for IL-6-mediated MM cell growth. In this study, we delineate the pattern of upstream MAPK cascade activation in IL-6-responsive B9 cells and in IL-6-nonresponsive U266, OCI-My5, and RPMI8226 MM cells to define sites of blockade of this pathway associated with loss of responsiveness to IL-6. In B9 cells, IL-6 triggered the following in sequence: gp130 phosphorylation, gp130-to-protein tyrosine phosphatase 1D (PTP1D) binding, PTP1D phosphorylation, PTP1D complex formation with Grb2-Son of sevenless 1 (Sos1), and Sos1 phosphorylation. gp130 phosphorylation, gp130-to-PTP1D binding, PTP1D phosphorylation, and PTP1D-to-Grb2 binding are also induced by IL-6 in all IL-6-independent MM cell lines studied. However, Grb2 is not associated with Sos1, and neither Grb2-to-Sos1 binding nor Sos1 phosphorylation is triggered by IL-6 in OCI-My5 MM cells. On the other hand, Grb2 and Sos1 are associated constitutively in U266 and RPMI8226 MM cells, but phosphorylation of Sos1 is not induced by IL-6. These data suggest that lack of Sos1 activation is associated with loss of IL-6 responsiveness in MM cell lines that grow independently of IL-6.

This article has been cited by other articles:

				L. Pedranzini, T. Dechow, M. Berishaj, R. Comenzo, P. Zhou, J. Azare, W. Bornmann, and J. Bromberg Pyridone 6, A Pan-Janus-Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells Cancer Res., October 1, 2006; 66(19): 9714 - 9721. [Abstract] [Full Text] [PDF]

				T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF]

				M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo Blood, June 1, 2005; 105(11): 4470 - 4476. [Abstract] [Full Text] [PDF]

				L. Duplomb, B. Chaigne-Delalande, P. Vusio, S. Raher, Y. Jacques, A. Godard, and F. Blanchard Soluble Mannose 6-Phosphate/Insulin-Like Growth Factor II (IGF-II) Receptor Inhibits Interleukin-6-Type Cytokine-Dependent Proliferation by Neutralization of IGF-II Endocrinology, December 1, 2003; 144(12): 5381 - 5389. [Abstract] [Full Text] [PDF]

				L. Quintanilla-Martinez, M. Kremer, K. Specht, J. Calzada-Wack, M. Nathrath, R. Schaich, H. Hofler, and F. Fend Analysis of Signal Transducer and Activator of Transcription 3 (Stat 3) Pathway in Multiple Myeloma: Stat 3 Activation and Cyclin D1 Dysregulation Are Mutually Exclusive Events Am. J. Pathol., May 1, 2003; 162(5): 1449 - 1461. [Abstract] [Full Text] [PDF]

				S. Lentzsch, M. Gries, M. Janz, R. Bargou, B. Dorken, and M. Y. Mapara Macrophage inflammatory protein 1-alpha (MIP-1alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells Blood, May 1, 2003; 101(9): 3568 - 3573. [Abstract] [Full Text] [PDF]

				M. Chatterjee, D. Honemann, S. Lentzsch, K. Bommert, C. Sers, P. Herrmann, S. Mathas, B. Dorken, and R. C. Bargou In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway Blood, October 16, 2002; 100(9): 3311 - 3318. [Abstract] [Full Text] [PDF]

				S. Greenstein, K. Ghias, N. L. Krett, and S. T. Rosen Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies Clin. Cancer Res., June 1, 2002; 8(6): 1681 - 1694. [Abstract] [Full Text] [PDF]

				M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis Blood, January 15, 2001; 97(2): 483 - 489. [Abstract] [Full Text] [PDF]

				W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau Multiple Myeloma Hematology, January 1, 2001; 2001(1): 157 - 177. [Abstract] [Full Text] [PDF]

				Y. Tu, A. Gardner, and A. Lichtenstein The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses Cancer Res., December 1, 2000; 60(23): 6763 - 6770. [Abstract] [Full Text]

				T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. E. Davies, Y.-T. Tai, S. P. Treon, B. Lin, R. L. Schlossman, P. Richardson, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood, November 1, 2000; 96(9): 2943 - 2950. [Abstract] [Full Text] [PDF]

				N.-L. Ge and S. Rudikoff Insulin-like growth factor I is a dual effector of multiple myeloma cell growth Blood, October 15, 2000; 96(8): 2856 - 2861. [Abstract] [Full Text] [PDF]

				T. Hideshima, D. Chauhan, G. Teoh, N. Raje, S. P. Treon, Y.-T. Tai, Y. Shima, and K. C. Anderson Characterization of Signaling Cascades Triggered by Human Interleukin-6 versus Kaposi's Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6 Clin. Cancer Res., March 1, 2000; 6(3): 1180 - 1189. [Abstract] [Full Text]

				G. Teoh, Y.-T. Tai, M. Urashima, S. Shirahama, M. Matsuzaki, D. Chauhan, S. P. Treon, N. Raje, T. Hideshima, Y. Shima, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines Blood, February 1, 2000; 95(3): 1039 - 1046. [Abstract] [Full Text] [PDF]

				F.-h. Xu, S. Sharma, A. Gardner, Y. Tu, A. Raitano, C. Sawyers, and A. Lichtenstein Interleukin-6-Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway Blood, July 1, 1998; 92(1): 241 - 251. [Abstract] [Full Text] [PDF]

				M. Hallek, P. Leif Bergsagel, and K. C. Anderson Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process Blood, January 1, 1998; 91(1): 3 - 21. [Full Text] [PDF]